NCT05867420View on ClinicalTrials.gov

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

PHASE1RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

ASKG915

ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.

Trial Locations (2)

10032

RECRUITING

Columbia University Irving Medical Center, New York

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

Sponsors
All Listed Sponsors
collaborator

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

INDUSTRY

lead

AskGene Pharma, Inc.

INDUSTRY

NCT05867420 - A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter